레카네맙 주사 시장 : 시장 규모, 점유율 및 성장 분석 - 적응증별, 유통 채널별, 최종 사용자별, 환자 연령층별, 투여 환경별, 지불자 유형별, 지역별 업계 예측(2026-2033년)

Global Lecanemab Injection Market size was valued at USD 1.16 Billion in 2024 and is poised to grow from USD 1.41 Billion in 2025 to USD 6.55 Billion by 2033, growing at a CAGR of 21.2% during the forecast period (2026-2033).

The global lecanemab injection market highlights a monoclonal antibody aimed at reducing amyloid-beta plaques in early Alzheimer's disease. Following years of ineffective trials, lecanemab stands out as a pioneering disease-modifying therapy, spurred by an increased need to address cognitive decline amid a growing aging population and rising dementia cases. Market dynamics have shifted from niche availability to substantial revenue potential, influenced by regulatory approvals and reimbursement negotiations that have made the therapy a viable treatment option. The integration of AI-driven patient selection is transforming the landscape by enabling precise targeting of early Alzheimer's candidates, enhancing trial efficiency, and facilitating quicker commercial deployment. This approach not only bolsters physician confidence and payer acceptance but also aligns with the advancements in regulatory frameworks, accelerating overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lecanemab Injection market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lecanemab Injection Market Segments Analysis

Global lecanemab injection market is segmented by indication, distribution channel, end user, patient age group, administration setting, payer type and region. Based on indication, no specific sub-segments were identified. Based on distribution channel, no specific sub-segments were identified. Based on end user, no specific sub-segments were identified. Based on patient age group, no specific sub-segments were identified. Based on administration setting, no specific sub-segments were identified. Based on payer type, no specific sub-segments were identified. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lecanemab Injection Market

The growing awareness among the public and caregivers regarding Alzheimer's disease plays a crucial role in enhancing early diagnosis, which in turn boosts the demand for disease-modifying therapies like lecanemab injection. Initiatives such as educational campaigns and advocacy organizations are pivotal in spreading knowledge about the disease's progression and the advantages of available treatments, prompting both patients and healthcare providers to seek out innovative solutions. This increased awareness not only diminishes the stigma related to cognitive decline but also encourages healthcare systems to adopt more progressive treatment methodologies. Consequently, this results in a broader patient base eligible for lecanemab, fostering sustained growth in the global market.

Restraints in the Global Lecanemab Injection Market

The high cost associated with lecanemab injection poses a significant challenge for both healthcare systems and patients, particularly in areas where reimbursement options are inadequate. This elevated price leads to increased out-of-pocket expenses, which in turn encourages healthcare providers to consider more affordable treatment alternatives whenever possible. Additionally, insurance companies frequently implement stringent utilization criteria that may result in delays or denials of coverage for qualified patients. Such financial pressures hinder market penetration, reduce adoption rates, and impede the overall expansion of the lecanemab injection market. Subsequently, insurers often require comprehensive cost-effectiveness studies prior to granting approvals.

Market Trends of the Global Lecanemab Injection Market

The Global Lecanemab Injection market is experiencing a notable trend towards community administration, as healthcare providers move the delivery of this treatment from specialty infusion centers to community hospitals and outpatient clinics. This transition enhances patient access by utilizing existing infrastructure, thereby reducing travel burdens for patients and caregivers, and improving medication adherence. The shift aligns with payer preferences for decentralized care models, as clinicians increasingly trust real-world outcome data to embrace Lecanemab in routine practice. Consequently, this broadening of the treatment's use beyond academic institutions is expected to drive sustained volume growth and expand the market reach across diverse geographical regions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Lecanemab Injection Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Mild Cognitive Impairment Due to Alzheimer's Disease
• Early Alzheimer's Disease

Global Lecanemab Injection Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Others

Global Lecanemab Injection Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Neurology Clinics
• Infusion Centers
• Others

Global Lecanemab Injection Market Size by Patient Age Group & CAGR (2026-2033)

• Market Overview
• Adult Patients
• Geriatric Patients

Global Lecanemab Injection Market Size by Administration Setting & CAGR (2026-2033)

• Market Overview
• Inpatient Administration
• Outpatient Administration

Global Lecanemab Injection Market Size by Payer Type & CAGR (2026-2033)

• Market Overview
• Public Payers
• Private Payers
• Self-Pay Patients

Global Lecanemab Injection Market Size & CAGR (2026-2033)

• North America (Indication, Distribution Channel, End User, Patient Age Group, Administration Setting, Payer Type)
  • US
  • Canada
• Europe (Indication, Distribution Channel, End User, Patient Age Group, Administration Setting, Payer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Distribution Channel, End User, Patient Age Group, Administration Setting, Payer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Distribution Channel, End User, Patient Age Group, Administration Setting, Payer Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Distribution Channel, End User, Patient Age Group, Administration Setting, Payer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acumen Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alzheon, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cognition Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annovis Bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cassava Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations